Fig. 3

Progression free survival in patients treated by RD triplets by the presence of high- risk cytogenetics

A – DRD regimen (daratumumab, lenalidomide, dexamethasone). B – KRD regimen (carfilzomib, lenalidomide, dexamethasone). C – E-IRD regimen („early “ ixazomib, lenalidomide, dexamethasone). D – L-IRD regimen („late “ ixazomib, lenalidomide, dexamethasone)